Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase NA 1

Status

Terminated 1Recruiting 1Active not recruiting 1

Sponsor Class

OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 86Lymphoid 63Other hematologic neoplasm 46CNS 7Myeloid 6Thoracic 5Genitourinary 5Breast 4Gynecologic 3Gastrointestinal 3Tumor-Agnostic 2Sarcoma 2Other 1Head & Neck 1Dermatologic 1Classical hematology 1

Conditions

Vomiting 1Nausea 1Lung Neoplasms 1Gastrointestinal Neoplasms 1Esophageal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Hepatocellular 1

Interventions

Oxaliplatin 1413Fluorouracil 1301Capecitabine 1087Gemcitabine 1045Leucovorin 932Irinotecan 818Bevacizumab 804Cisplatin 669Radiotherapy 536Cetuximab 470pembrolizumab 428Paclitaxel 390Nivolumab 337130-nm albumin-bound paclitaxel 325Drug Therapy 314Docetaxel 287S 1 (combination) 274Sorafenib 266Folfox protocol 261Albumin-Bound Paclitaxel 259sintilimab 211durvalumab 210Surgical Procedures, Operative 204tislelizumab 203Radiosurgery 202lenvatinib 201apatinib 200Carboplatin 187Magnetic Resonance Spectroscopy 183regorafenib 181

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × dexamethasone acetate × Gastrointestinal × Clear all
NCT07617246 2026-06-01

The Efficacy and Safety of Fosrolapitant and Palonosetron Hydrochloride for Injection in Preventing Nausea and Vomiting Caused by Multi-cycle Immunotherapy and Chemotherapy in Patients With Esophageal Cancer and Lung Cancer

Second Affiliated Hospital, School of Medicine, Zhejiang University

Phase 2 Recruiting
120 enrolled
GastrointestinalThoracic

Esophageal Neoplasms, Lung Neoplasms

NCT04251715 2025-04-18

mFOLFIRINOX Followed by Hepatic Arterial Infusion of Floxuridine and Dexamethasone With Systemic mFOLFIRI for Unresectable Liver-dominant Intrahepatic Cholangiocarcinoma

OHSU Knight Cancer Institute

Phase 2 Active not recruiting
5 enrolled
Gastrointestinal

Carcinoma, Hepatocellular, Cholangiocarcinoma

NCT02550119 2017-03-28

Dolasetron Mesylate and Dexamethasone With or Without Aprepitant in Preventing Nausea and Vomiting in Patients Undergoing Oxaliplatin-Containing Chemotherapy for Gastrointestinal Malignancy

University of Southern California

Phase NA Terminated
19 enrolled
Gastrointestinal

Gastrointestinal Neoplasms, Nausea, Vomiting

Data powered by HemOnc (CC BY 4.0) Colophon âš¡